Pallomino Therapeutics

Selective small-molecule modulators of disease-relevant human cytochrome P450 enzymes

Pallomino Therapeutics is an early-stage drug discovery company developing a massively parallel, cell-based platform to identify selective inhibitors and allosteric modulators of human cytochrome P450 enzymes.Our initial focus is on CNS-relevant targets, including CYP46A1 and cholesterol metabolism in neurological disease.